1. Pink Sheet
  2. >>Legislation

USMCA Trade Negotiations: Could US House Dems' Talks Open Door For AAM Changes?

 
• By Brenda Sandburg

Biologics exclusivity remains a contentious issue as US Trade Representative and House Democrats begin discussions on the trade pact with Mexico and Canada.  

United States Mexico Canada Agreement, USMCA concept. 3D rendering

When the United States-Mexico-Canada Agreement was signed in November, it seemed like the Association for Accessible Medicines and other stakeholders faced an uphill battle to alter its provisions. But some members of the US Congress were sympathetic to their arguments, with House Democrats, for example, setting up working groups to engage in further discussions with the US Trade Representative.

And during a recent Senate hearing, some legislators expressed concerns that the USMCA trade pact could limit their options to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.